Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lonza Group Ltd ( (CH:LONN) ) just unveiled an update.
Lonza Group Ltd reported strong financial results for the first half of 2025, with sales reaching CHF 3.6 billion and a core EBITDA of CHF 1.1 billion. The company raised its revenue and margin forecasts for the CDMO business for the full year, expecting sales growth of 20-21% and a core EBITDA margin of 30-31%. The positive performance was driven by high utilization of facilities, ongoing commercial momentum, and successful integration of the Vacaville site. Lonza’s Capsules & Health Ingredients business also showed improvement, with a stable sales outlook and an improved core EBITDA margin. The company continues to monitor geopolitical and macroeconomic conditions, with no significant financial impact expected from US trade policy. Lonza’s new production facilities in Visp and Stein are progressing as planned, and the company remains focused on expanding its market position through its One Lonza strategy.
The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF645.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza Group Ltd is a leading company in the biopharmaceutical industry, specializing in contract development and manufacturing organization (CDMO) services. The company’s primary focus is on providing a wide range of services, including mammalian, bioconjugates, and small molecule technologies, to support the biopharma industry. Lonza is known for its global network and integrated multi-technology offerings, which position it as a preferred partner in the sector.
Average Trading Volume: 131,288
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF38.93B
For an in-depth examination of LONN stock, go to TipRanks’ Overview page.